HYPK

Summary

HYPK (huntingtin interacting protein K, HGNC:18418) is a protein-coding gene on chromosome 15q15.3, encoding Huntingtin-interacting protein K (Q9NX55). Component of several N-terminal acetyltransferase complexes. It is a common-essential gene (DepMap: required in 92.7% of cancer cell lines).

Enables protein folding chaperone. Involved in negative regulation of apoptotic process and protein stabilization. Located in cytoplasm; microtubule cytoskeleton; and nucleoplasm. Part of protein-containing complex.

Source: NCBI Gene 25764 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 20 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 92.7% of screened cell lines (common-essential)
• MANE Select transcript: NM_016400

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18418
Approved symbol	HYPK
Name	huntingtin interacting protein K
Location	15q15.3
Locus type	gene with protein product
Status	Approved
Aliases	HSPC136, FLJ20431
Ensembl gene	ENSG00000242028
Ensembl biotype	protein_coding
OMIM	612784
Entrez	25764

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000406925, ENST00000442995, ENST00000458412, ENST00000497142, ENST00000498605

RefSeq mRNA: 2 — MANE Select: NM_016400 NM_001199885, NM_016400

CCDS: CCDS10104

Canonical transcript exons

ENST00000442995 — 4 exons

Exon	Start	End
ENSE00001562216	43800599	43800784
ENSE00003518538	43801518	43801569
ENSE00003685895	43801132	43801187
ENSE00004282328	43801711	43804427

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 91.64.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 79.3787 / max 1097.7497, expressed in 1826 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146356	79.3787	1826

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	91.64	gold quality
gastrocnemius	UBERON:0001388	91.41	gold quality
muscle of leg	UBERON:0001383	91.11	gold quality
skeletal muscle tissue	UBERON:0001134	90.87	gold quality
heart left ventricle	UBERON:0002084	89.91	gold quality
left adrenal gland	UBERON:0001234	89.55	gold quality
monocyte	CL:0000576	89.44	gold quality
left adrenal gland cortex	UBERON:0035825	89.39	gold quality
right adrenal gland	UBERON:0001233	88.95	gold quality
leukocyte	CL:0000738	88.87	gold quality
apex of heart	UBERON:0002098	88.73	gold quality
mucosa of transverse colon	UBERON:0004991	88.48	gold quality
adrenal gland	UBERON:0002369	88.37	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.35	gold quality
right atrium auricular region	UBERON:0006631	88.35	gold quality
ganglionic eminence	UBERON:0004023	88.34	gold quality
substantia nigra	UBERON:0002038	88.32	gold quality
right adrenal gland cortex	UBERON:0035827	88.19	gold quality
heart	UBERON:0000948	88.16	gold quality
muscle tissue	UBERON:0002385	88.07	gold quality
prefrontal cortex	UBERON:0000451	87.85	gold quality
right lobe of liver	UBERON:0001114	87.80	gold quality
adenohypophysis	UBERON:0002196	87.59	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.51	gold quality
hypothalamus	UBERON:0001898	87.31	gold quality
liver	UBERON:0002107	87.24	gold quality
pituitary gland	UBERON:0000007	87.05	gold quality
cerebellum	UBERON:0002037	86.99	gold quality
cerebellar cortex	UBERON:0002129	86.95	gold quality
cerebellar hemisphere	UBERON:0002245	86.92	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.01
E-GEOD-106540	no	307.72
E-MTAB-6379	no	281.74
E-GEOD-93593	no	7.03

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HSF1

miRNA regulators (miRDB)

32 targeting HYPK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-5590-5P	98.81	68.78	969
HSA-MIR-34B-3P	98.70	67.40	1171
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-432-5P	98.00	68.13	989
HSA-MIR-8086	97.21	64.13	331

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 92.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 17)

• The present study, has confirmed, by confocal microscopy and immunoprecipitation, that HYPK interacts with the N-terminal of Htt. (PMID:17947297)
• HYPK has roles in regulating cell growth, cell cycle, unfolded protein response and cell death (PMID:23272104)
• maintenance of HYPK expression by HSF1 is necessary for the survival of cells under thermal stress conditions (PMID:24361604)
• Chaperone-like protein HYPK is induced by cellular stress and is under transcriptional regulation by HSF1. (PMID:24465598)
• By virtue of its flexibility and nascent peptide binding activity, HYPK may play an important role in assisting protein (re)folding. (PMID:25116620)
• specific interaction of HYPK with HTT-N17 is crucial for the chaperone activity of HYPK (PMID:25446099)
• HYPK can act as negative regulator of heat shock response by repressing transcriptional activity of HSF1. (PMID:27017930)
• Results show that HYPK, possibly with its interacting partners, induces autophagy. results further confirm that HYPK could also be involved in clearing mutant HTT aggregates by augmenting autophagy pathway. (PMID:27067261)
• In combination with acetylation assays, the HypK N-terminal region is identified as a negative regulator of the NatA acetylation activity (PMID:28585574)
• study provides evidence of the existence of disordered nanostructure in HYPK protein that mechanistically plays a decisive role in preventing both self and non-self protein aggregation. (PMID:29381348)
• Results find that HYPK harbors intrinsic hNatA-specific inhibitory activity through a bipartite structure: a ubiquitin-associated domain that binds a hNaa15 metazoan-specific region and an N-terminal loop-helix region that distorts the hNaa10 active site. (PMID:29754825)
• this studu identified the metastable states in the seeds of the Ubiquitin associated (UBA) domain of Huntingtin Interacting Protein K (HYPK). (PMID:30251673)
• Results find the novel mode of internal ribosome entry site (IRES)-dependent translation initiation of HYPK mRNA, along with the determination of mechanism of the nuclear localization process of HYPK. (PMID:31397627)
• Huntingtin interacting protein K (HYPK) forms a tetrameric complex with the human N-terminal acetyltransferase E (NatE). HYPK exhibits negative cooperative binding to NAA15 auxiliary subunit by inducing NAA15 shifts in opposing directions. HYPK inhibits NAA10 and NAA50 catalytic activities through structural alteration of the NAA10 and the NatE substrate-binding sites, respectively. (PMID:32042062)
• HYPK coordinates degradation of polyneddylated proteins by autophagy. (PMID:34836490)
• Phosphorylation of Arl4A/D promotes their binding by the HYPK chaperone for their stable recruitment to the plasma membrane. (PMID:35857868)
• HYPK: A marginally disordered protein sensitive to charge decoration. (PMID:38657047)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	hypk	ENSDARG00000059725
mus_musculus	Hypk	ENSMUSG00000027245
rattus_norvegicus	Hypk	ENSRNOG00000072345
drosophila_melanogaster	CG9922	FBGN0038196
caenorhabditis_elegans	F13G3.10	WBGENE00008768

Protein

Protein identifiers

Huntingtin-interacting protein K — Q9NX55 (reviewed: Q9NX55)

Alternative names: Huntingtin yeast partner K

All UniProt accessions (2): Q9NX55, J3QT56

UniProt curated annotations — full annotation on UniProt →

Function. Component of several N-terminal acetyltransferase complexes. Inhibits the N-terminal acetylation activity of the N-terminal acetyltransferase NAA10-NAA15 complex (also called the NatA complex). Has chaperone-like activity preventing polyglutamine (polyQ) aggregation of HTT in neuronal cells probably while associated with the NatA complex. May play a role in the NatA complex-mediated N-terminal acetylation of PCNP.

Subunit / interactions. Component of the N-terminal acetyltransferase A (NatA)/HYPK complex at least composed of NAA10, NAA15 and HYPK, which has N-terminal acetyltransferase activity. Within the complex interacts with NAA10. Within the complex interacts with NAA15. Predominantly interacts with NAA15 in the NAA10-NAA15 complex (also called the NatA complex); the interaction with the NatA complex reduces the acetylation activity of the NatA complex. Interacts with HTT (via N-terminus). The NatA complex is required for HYPK stability and for reducing polyQ aggregation of HTT. Component of the N-terminal acetyltransferase E (NatE)/HYPK complex at least composed of NAA10, NAA15, NAA50 and HYPK. Within the complex interacts with NAA10 and NAA15. Does not interact with NAA50. Interaction with NAA15 reduces the capacity of NAA15 to interact with NAA50. Its capacity to interact with the NatA complex is reduced by NAA50. Does not interact with the N-terminal acetyltransferase B (NatB) complex component NAA25 or the N-terminal acetyltransferase C (NatC) complex component NAA35.

Subcellular location. Nucleus. Cytoplasm.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NX55-2	2	yes
Q9NX55-3	3

RefSeq proteins (2): NP_001186814, NP_057484* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR038922	HYPK_UBA	Domain
IPR044034	NAC-like_UBA	Domain
IPR052617	Huntingtin-int_K	Family

Pfam: PF19026

UniProt features (22 total): helix 5, mutagenesis site 4, compositionally biased region 3, region of interest 2, turn 2, splice variant 2, chain 1, sequence variant 1, coiled-coil region 1, modified residue 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6C95	X-RAY DIFFRACTION	3.15
9F1D	ELECTRON MICROSCOPY	3.26
6PW9	ELECTRON MICROSCOPY	4.03

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NX55-F1	70.87	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 30

Mutagenesis-validated functional residues (4):

Position	Phenotype
28	reduces ability to inhibit naa10-naa15 complex-mediated n-terminal acetylation, which results in increased n-terminal ac
35	reduces ability to inhibit naa10-naa15 complex-mediated n-terminal acetylation, which results in increased n-terminal ac
38	reduces ability to inhibit naa10-naa15 complex-mediated n-terminal acetylation, which results in increased n-terminal ac
52–121	abolishes interaction with naa10 and naa15.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 89 (showing top): GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, NKX61_01, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_STABILIZATION, GOBP_PROTEIN_FOLDING, GOBP_REGULATION_OF_PROTEIN_STABILITY, HAND1E47_01, SCGGAAGY_ELK1_02, KIM_MYCN_AMPLIFICATION_TARGETS_UP, TCANNTGAY_SREBP1_01, LU_EZH2_TARGETS_DN, KRIEG_KDM3A_TARGETS_NOT_HYPOXIA, CSR_LATE_UP.V1_UP, GOMF_PROTEIN_FOLDING_CHAPERONE, LTE2_UP.V1_UP

GO Biological Process (3): negative regulation of apoptotic process (GO:0043066), protein stabilization (GO:0050821), protein folding (GO:0006457)

GO Molecular Function (2): protein folding chaperone (GO:0044183), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), microtubule cytoskeleton (GO:0015630), protein-containing complex (GO:0032991)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
regulation of protein stability	1
cellular process	1
protein maturation	1
molecular_function	1
protein folding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoskeleton	1
cellular_component	1

Protein interactions and networks

STRING

1161 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HYPK	NAA15	Q9BXJ9	983
HYPK	NAA10	P41227	977
HYPK	NAA50	Q9GZZ1	976
HYPK	HTT	P42858	965
HYPK	NAA16	Q6N069	724
HYPK	NAA60	Q9H7X0	682
HYPK	SERF2	P84101	620
HYPK	NAA20	P61599	619
HYPK	NAA25	Q14CX7	612
HYPK	NAA40	Q86UY6	597
HYPK	NAA30	Q147X3	520
HYPK	PCNP	Q8WW12	519
HYPK	NAA11	Q9BSU3	503
HYPK	NAA80	Q93015	489
HYPK	FAM98A	Q8NCA5	454

IntAct

41 interactions, top by confidence:

A	B	Type	Score
NAA15	NAA10	psi-mi:“MI:0914”(association)	0.840
NAA15	HYPK	psi-mi:“MI:0915”(physical association)	0.840
HYPK	TXLNA	psi-mi:“MI:0915”(physical association)	0.720
TXLNA	HYPK	psi-mi:“MI:0915”(physical association)	0.720
HTT	HYPK	psi-mi:“MI:0915”(physical association)	0.670
HYPK	HTT	psi-mi:“MI:0915”(physical association)	0.670
HYPK	NAA10	psi-mi:“MI:0914”(association)	0.640
MAGEA1	HYPK	psi-mi:“MI:0915”(physical association)	0.560
HYPK	MAGEA1	psi-mi:“MI:0915”(physical association)	0.560
C2orf68	HYPK	psi-mi:“MI:0915”(physical association)	0.560
NAA10	OFD1	psi-mi:“MI:0914”(association)	0.480
Naa10	NAA10	psi-mi:“MI:0915”(physical association)	0.400
Naa15	NAA10	psi-mi:“MI:0915”(physical association)	0.400
Naa10	MYO9A	psi-mi:“MI:0914”(association)	0.350
Naa11		psi-mi:“MI:0914”(association)	0.350
Naa50	WDR46	psi-mi:“MI:0914”(association)	0.350
Naa15	TBX3	psi-mi:“MI:0914”(association)	0.350
KSR1	FBLL1	psi-mi:“MI:0914”(association)	0.350
TSGA10IP	NAA10	psi-mi:“MI:0914”(association)	0.350
HYPK	APOA1	psi-mi:“MI:0914”(association)	0.350
ALPK2	C2CD4B	psi-mi:“MI:0914”(association)	0.350
NAA11	DVL2	psi-mi:“MI:0914”(association)	0.350
HYPK	RPSA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (169): HYPK (Two-hybrid), TXLNA (Two-hybrid), HYPK (Affinity Capture-MS), HYPK (Co-fractionation), HYPK (Co-fractionation), HYPK (Co-fractionation), NAA15 (Co-fractionation), NAA16 (Co-fractionation), SPG20 (Co-fractionation), HYPK (Proximity Label-MS), HYPK (Affinity Capture-MS), HYPK (Affinity Capture-MS), HYPK (Affinity Capture-MS), HYPK (Affinity Capture-MS), HTT (Affinity Capture-MS)

ESM2 similar proteins: A1CMF8, A1DLM0, A2R4V1, A4RC89, A6R641, A6SB28, A7EIZ1, P0C2C7, Q0UKB5, Q13765, Q1DHR3, Q2H4Z2, Q2KIA6, Q2PFU1, Q2TBV6, Q2U955, Q4P341, Q4WD81, Q5AYK0, Q5B187, Q5E9A1, Q5R8X8, Q5R9I9, Q5ZIN1, Q60817, Q61UX1, Q68F90, Q6ICZ8, Q6IP73, Q6PFL6, Q6QN10, Q7SI17, Q7SYJ9, Q86S66, Q8AWF2, Q8JIU7, Q8LCV1, Q8LH03, Q8RWU7, Q94518

Diamond homologs: Q2PFU1, Q9CR41, Q9NX55

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	16
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2269 predictions. Top by Δscore:

Variant	Effect	Δscore
15:43796656:G:C	donor_gain	1.0000
15:43798030:A:T	acceptor_gain	1.0000
15:43800781:GACG:G	donor_gain	1.0000
15:43800783:CGG:C	donor_loss	1.0000
15:43800785:G:GG	donor_gain	1.0000
15:43800785:GT:G	donor_loss	1.0000
15:43800786:T:A	donor_loss	1.0000
15:43801184:AGCGG:A	donor_loss	1.0000
15:43801185:GCG:G	donor_gain	1.0000
15:43801188:G:C	donor_loss	1.0000
15:43801188:G:GG	donor_gain	1.0000
15:43801189:T:A	donor_loss	1.0000
15:43801512:TTGCA:T	acceptor_loss	1.0000
15:43801513:TGCA:T	acceptor_loss	1.0000
15:43801514:GCA:G	acceptor_loss	1.0000
15:43801516:A:AG	acceptor_gain	1.0000
15:43801516:A:AT	acceptor_loss	1.0000
15:43801516:AG:A	acceptor_gain	1.0000
15:43801517:G:GA	acceptor_loss	1.0000
15:43801517:G:GG	acceptor_gain	1.0000
15:43801517:GG:G	acceptor_gain	1.0000
15:43801517:GGGA:G	acceptor_gain	1.0000
15:43801568:TA:T	donor_gain	1.0000
15:43801570:G:GG	donor_gain	1.0000
15:43796223:CATTG:C	acceptor_gain	0.9900
15:43796225:T:TC	acceptor_gain	0.9900
15:43796228:C:CC	acceptor_gain	0.9900
15:43796655:AG:A	donor_gain	0.9900
15:43796673:T:C	donor_gain	0.9900
15:43796941:C:CC	acceptor_gain	0.9900

AlphaMissense

841 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:43800726:T:C	L43S	1.000
15:43800735:T:A	V46D	1.000
15:43800738:C:T	T47I	1.000
15:43801133:C:A	A63D	1.000
15:43801529:T:C	L85P	1.000
15:43801531:G:C	A86P	1.000
15:43801538:T:A	V88D	1.000
15:43801544:T:A	I90N	1.000
15:43801754:T:C	L113S	1.000
15:43801768:G:C	G118R	1.000
15:43801769:G:T	G118V	1.000
15:43801787:T:C	L124P	1.000
15:43800704:C:G	H36D	0.999
15:43800713:G:C	G39R	0.999
15:43800719:G:C	A41P	0.999
15:43800722:G:C	D42H	0.999
15:43800723:A:G	D42G	0.999
15:43800723:A:T	D42V	0.999
15:43800724:C:A	D42E	0.999
15:43800724:C:G	D42E	0.999
15:43800726:T:G	L43W	0.999
15:43800732:G:C	R45P	0.999
15:43800735:T:C	V46A	0.999
15:43800740:G:C	D48H	0.999
15:43800741:A:T	D48V	0.999
15:43800746:G:C	A50P	0.999
15:43800762:T:C	I55T	0.999
15:43801132:G:C	A63P	0.999
15:43801138:T:C	S65P	0.999
15:43801145:T:A	I67N	0.999

dbSNP variants (sampled 300 via entrez): RS1000068099 (15:43802476 C>T), RS1000288190 (15:43802217 G>A,C), RS1000840249 (15:43804790 A>G), RS1001291988 (15:43803325 T>A), RS1001935656 (15:43803205 A>G), RS1003413902 (15:43804652 C>T), RS1003632042 (15:43804324 A>C), RS1004404847 (15:43803861 G>C), RS1004823575 (15:43804873 A>G), RS1004900883 (15:43803635 CAA>C,CA,CAAA), RS1005404826 (15:43802751 A>G), RS1005493589 (15:43802555 G>A,T), RS1005966945 (15:43798848 C>A), RS1007217976 (15:43804283 C>T), RS1007293808 (15:43798638 A>G)

Disease associations

OMIM: gene MIM:612784 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066284 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.72	Kd	18.84	nM	CHEMBL5653589
7.72	ED50	18.84	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148564: Binding affinity to human HYPK incubated for 45 mins by Kinobead based pull down assay	kd	0.0188	uM

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases expression, decreases expression, increases abundance	3
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, affects expression	1
bisphenol A	increases expression	1
sodium arsenate	decreases expression	1
beta-lapachone	increases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
microcystin RR	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
ICG 001	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Irinotecan	affects expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Coumestrol	increases expression	1
Dexamethasone	affects cotreatment, affects expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, affects expression	1
Ivermectin	decreases expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Rotenone	decreases expression	1
Tretinoin	affects cotreatment, increases expression	1
Urethane	decreases expression	1
Valproic Acid	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651606	Binding	Binding affinity to human HYPK incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.